BioSeek and UCB Establish Compound Evaluation Collaboration and Expand Previous Agreement
News Jan 08, 2009
BioSeek, Inc. has announced that it has entered into a new and expanded agreement with UCB, a global biopharmaceutical company based in Belgium.
Under the collaboration, BioSeek will, over the next year, both carry out broad-based profiling of selected UCB new chemical and biological entities, and guide lead optimization of a specific phenotypic hit previously identified by UCB and further characterized in BioMAP screens.
According to the terms of the agreement, BioSeek will receive various payments from UCB, including an upfront technology license fee, research funding, and preclinical and clinical milestone payments based on candidate advancement enabled by the BioMAP platform.
“UCB’s decision to expand its relationship with BioSeek is an important validation of our work and technology. Our 2007 collaboration identified specific areas of high interest to UCB where the BioMAP platform could be productively applied to UCB projects, and those form the basis of the new agreement encompassing two major programs in bioactive annotation and lead optimization,” said Michael C. Venuti, Ph.D., Chief Executive Officer of BioSeek. “The success of this collaboration demonstrates the broad utility of our BioMAP platform of predictive human biology screens to enhance and accelerate drug discovery.”
“Our previous project with UCB clearly showed that, by combining proper study design and attention to detailed follow-up, the BioMAP systems can be used to identify and advance promising molecules through preclinical evaluation in a way complementary to target-based drug discovery. By focusing on pharmacological outcome in a defined set of validated human cell-based screens, novel bioactivity can be detected, and anecdotally observed activity can be optimized. We look forward to working with UCB on these two major projects in the coming year,” added Dr. Venuti.
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018